State coverage
Iowa Medicaid and GLP-1 coverage
Medicaid, for obesity: Other diagnoses only. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Wegovy and Zepbound are Preferred on the drug list, but its own footnote excludes the weight-loss indication.
- Appeal deadline
- 90 days from the date on the notice of decision if your Medicaid is fee-for-service; 120 days from your health plan's own appeal decision if you are in managed care source
- Date read
- September 2026
Iowa Medicaid's pharmacy benefit runs off one statewide Preferred Drug List, and on first read it looks generous: Wegovy and Zepbound both sit in the Endocrine Metabolic Agents class as Preferred brand drugs, with no non-preferred detour required. Read the footnote attached to both, though, and the generosity narrows fast — it exists to route the drugs toward specific FDA-approved uses, and weight loss is not among them.
The document that does the routing is a dedicated prior-authorization form for incretin mimetics prescribed outside a diabetes diagnosis. It opens by naming the thing it will not pay for, then lays out three doors that are not that: reducing cardiovascular risk in a patient with established heart disease, treating obstructive sleep apnea, and treating a liver condition called MASH. Each door has its own BMI floor, its own specialist-involvement requirement, and its own maintenance-dose ceiling.
A second, separate class handles the same molecules prescribed for type 2 diabetes — Ozempic, Rybelsus, Trulicity, Victoza and the rest — under an ordinary metformin-trial-first structure. Wegovy and Zepbound do not appear in that class at all; Iowa keeps the diabetes and non-diabetes uses of these drugs on entirely separate prior-authorization tracks.
The state's own pharmacy provider manual states the underlying rule in the plainest terms available: Medicaid does not pay for drugs used to cause weight loss. That line predates the GLP-1s by years and traces back to the same federal Medicaid carve-out most states rely on. Iowa's newer form does not repeal it — it built two or three narrow, medically specific doors through it.
What we could verify for Iowa
The state's drug list carries an Endocrine Metabolic Agents class and places the newer drugs in it as Preferred, each flagged with the same comment. The list defines Comment 12 as: "PA Required. Weight loss indication not covered." Both Wegovy and Zepbound are listed as Brand, Preferred, Comment 12.
Iowa Department of Health and Human Services, Iowa Medicaid Preferred Drug List, effective January 2026 · source
The state's non-diabetes prior authorization form opens with the exclusion, not the exception: "Prior authorization (PA) is required for incretin mimetics not otherwise covered by the Anti-Diabetics Non-Insulin Agents PA criteria for covered FDA approved for compendia indications. Payment for excluded medical use(s) (e.g. weight loss), as defined in the Iowa State Plan and Iowa Administrative Code 441 – 78.2(4) will be denied." What follows are three qualifying uses: reducing the risk of "major adverse cardiovascular events (MACE)" in a patient with established cardiovascular disease and a BMI of 27 or higher (Wegovy only); moderate-to-severe obstructive sleep apnea with a BMI of 30 or higher and a documented apnea-hypopnea index of 15 or more (Zepbound only); and "noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)" with confirmed liver fibrosis (Wegovy only).
Iowa Department of Health and Human Services, Request for Prior Authorization — Incretin Mimetics for Non-Diabetes Indications (Form 470-0058), effective January 2026 · source
The pharmacy provider manual's list of drugs excluded from coverage opens with this line: "Medicaid payment will not be made for: Drugs used to cause anorexia, weight gain or weight loss." The same manual separately lists "GLP-1 Agonist/Basal Insulin Combinations" among the drug classes that carry their own prior-authorization criteria for diabetes use. The chapter is stamped "Revised October 21, 2022" on every page and is still the version hosted at hhs.iowa.gov.
Iowa Department of Health and Human Services, Providers' Manual — Prescribed Drugs, Chapter III, effective October 2022 · source
A second, older prior authorization criteria document — covering the ordinary diabetes-indicated class rather than the non-diabetes carve-out — states the same rule for that class in one sentence: "Requests for weight loss are not a covered diagnosis of use and will be denied." That line sits directly under the criteria for "Anti-Diabetics, Non-Insulin Agents," the class that includes the diabetes-indicated GLP-1s.
Iowa Department of Health and Human Services, Iowa Medicaid Drug Prior Authorization Criteria, effective July 2024 · source
Iowa's appeals overview states two different clocks depending on the path. For a standard fee-for-service Medicaid appeal: "the appellant must file the appeal before the 90th day following the date on the NOD [Notice of Decision]." For a managed-care member who has already gone through the plan's own appeal: "A hearing will be held if the state fair hearing appeal request is made within 120 calendar days of the date on the MCO appeal determination."
Iowa Department of Health and Human Services, Administrative Rules and Appeals Bureau, Appeals Process Overview · source
Iowa is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. Iowa Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Iowa with the rest in the coverage matrix.
If you work for the State of Iowa
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: State of Iowa employee health plan (Iowa Choice / National Choice, administered by Wellmark). Its pharmacy benefit runs through Wellmark, on its Blue Rx Value Plus drug list.
Weight reduction drugs excluded
The State of Iowa plan excludes weight reduction drugs under the pharmacy benefit, and its medical exclusions cover weight-reduction prescription drugs even when weight loss is medically appropriate. Bariatric surgery is listed as covered.
"Drugs, services, and items that are not ... covered under your prescription drug ... benefits include, but are not limited to:" ... "Weight reduction drugs."
Wellmark, State of Iowa Iowa Choice Benefit Booklet (Wellmark Blue HMO / BlueRx Value Plus Prescription Drug Plan), effective January 2026 · source
The National Choice (PPO) booklet carries the same pharmacy exclusion: "Weight reduction drugs."
Wellmark, State of Iowa National Choice Benefit Booklet, effective January 2026 · source
The medical exclusions list "Weight reduction programs or supplies ... (including dietary supplements, foods, ... equipment, lab testing, examinations, ... and prescription drugs), whether or not" weight reduction is medically appropriate.
Wellmark, State of Iowa Iowa Choice Benefit Booklet (Wellmark Blue HMO / BlueRx Value Plus Prescription Drug Plan), effective January 2026 · source
Under "Services Your Plan Generally Does NOT Cover" the 2026 summary lists "Weight loss programs" and "Some pharmacy drugs are not covered"; "Bariatric surgery" is listed under other covered services.
State of Iowa, Summary of Benefits and Coverage, Iowa Choice Active HMO, coverage period 01/01/2026-12/31/2026, effective January 2026 · source
"The State of Iowa offers employees one health plan (administered by Wellmark Blue Cross and Blue Shield)". Drugs on the "Prescription Drug Coverage (Blue Rx Value Plus Formulary)" cost a $10, $25 or $50 copay for a 30-day retail supply by tier.
Iowa Department of Administrative Services, 2026 Benefits at a Glance, effective January 2026 · source
If the appeal fails, or you cannot wait
Iowa Medicaid excludes weight loss but can still approve these drugs for another approved use, set out in the facts above. If none of those applies to you, cash-pay telehealth is the fallback: you pay the whole cost yourself, with no Medicaid help.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerMEDGmCheck availability | GLP-1 injections from $179 and tablets from $249. Brand options are a membership plus the drug's own cost: $99 for Zepbound or Wegovy, $171 for Ozempic. It discloses AI content and actor imagery. |
| PartnerBodybuilding Health+Check availability | Compounded tirzepatide at $174.67 to $209 a month, lower the more months you buy at once; semaglutide is tiered the same way. Operated by Dynamo Group LLC. |
| PartnerStrut HealthCheck availability | A telehealth storefront where weight loss is one of six categories. No GLP-1 price is published on the page our link opens. |
| PartnerRxSpan MDCheck availability | Multi-category telehealth that promises transparent pricing, then publishes no GLP-1 price on the page our link opens. |
| PartnerSnagRxCheck availability | Compounded semaglutide at $69 a month and tirzepatide at $119, the same at every dose, with no membership. Both are countdown sale prices, marked down from $299 and $399. Not available in Louisiana. |
| PartnerSkinnyRxCheck availability | Compounded semaglutide and tirzepatide injections at $99 for the first month, tablets at $149 and $199. No second-month price is printed for any of them. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in September 2026, and they change often. Check the current number before you buy.
Where this comes from
- Iowa Department of Health and Human Services, Iowa Medicaid Preferred Drug List, effective January 2026 — Open the document
- Iowa Department of Health and Human Services, Request for Prior Authorization — Incretin Mimetics for Non-Diabetes Indications (Form 470-0058), effective January 2026 — Open the document
- Iowa Department of Health and Human Services, Providers' Manual — Prescribed Drugs, Chapter III, effective October 2022 — hhs.iowa.gov/media/7769/download?inline=
- Iowa Department of Health and Human Services, Iowa Medicaid Drug Prior Authorization Criteria, effective July 2024 — hhs.iowa.gov/media/13645/download?inline=
- Iowa Department of Health and Human Services, Administrative Rules and Appeals Bureau, Appeals Process Overview — hhs.iowa.gov/media/607/download